Clinical and Translational Oncology

, Volume 15, Issue 4, pp 265–270 | Cite as

Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer

  • Pedro Villarejo-CamposEmail author
  • David Padilla-Valverde
  • Raúl Martin Martin
  • Pablo Menéndez-Sánchez
  • Teófilo Cubo-Cintas
  • Jose Antonio Bondia-Navarro
  • Jesús Martín Fernández
Research Article



Angiogenesis and lymphangiogenesis are essential processes for the formation of blood and lymphatic vessels that allow tumour growth and spread. The binding of VEGF and VEGF-C factors with their receptors (VEGFR2, VEGFR3) in endothelial cells triggers signals that regulate these processes. We compared preoperative serum VEGF and VEGF-C levels with samples obtained after completion of surgery and adjuvant treatment in patients with gastric cancer. In addition, we determined the prognostic value and relationship to survival of serum VEGF and VEGF-C levels.


We used a prospective cohort study of 59 gastric cancer patients who underwent surgery. Serum VEGF and VEGF-C were measured by enzyme-linked immunosorbent assay (ELISA) the day before surgery and 6 months later, after completion of adjuvant treatment.


Serum VEGF values decreased after treatment in patients with resectable tumours (mean ± SD) (405.42 ± 298.38 vs. 306.38 ± 212.47 pg/ml; p < 0.01), poorly differentiated and undifferentiated tumours (G3, G4) (438 ± 339.71 vs. 322.47 ± 210.71 pg/ml; p = 0.01), locally advanced gastric tumours (T4 stage) (424.27 ± 323.08 vs. 333.62 ± 221.72 pg/ml; p = 0.03) and tumours with a greater number of involved regional lymph nodes (N3) (442.38 ± 311.52 vs. 337.4 ± 203.64 pg/ml; p = 0.04). Serum preoperative VEGF values over 761 pg/ml were associated with shorter patient survival. The mean overall survival time for patients with serum VEGF levels higher than 761 pg/ml was 7 ± 2.99 months (95 % CI 1.14–12.86) while for patients with serum VEGF levels of less than 761 pg/ml was 21.18 ± 2.88 (95 % CI 15.54–26.83) The mean disease-specific survival time for patients with serum VEGF levels higher than 761 pg/ml was 6.25 ± 2.53 months (95 % CI 1.29–11.21) while for patients with serum VEGF levels of less than 761 pg/ml was 27.57 ± 3.45 (95 % CI 20.80–34.35). Multivariate analysis identified preoperative serum VEGF levels as an independent prognostic factor (HR = 0.144; p = 0.03).


Serum VEGF levels decreased after the completion of treatment in patients with resected tumours, suggesting VEGF tracking may be useful in monitoring progression. Preoperative measurement of serum VEGF may help us identify patients with a poor prognosis.


Gastric cancer Serum VEGF Serum VEGF-C Angiogenesis Lymphangiogenesis Lymph node metastasis Survival 


Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65–71PubMedGoogle Scholar
  2. 2.
    Cheong JH, Hong SY, Zheng Y, Noh SH (2011) Eupatilin inhibits gastric cancer cell growth by blocking STAT3-mediated VEGF expression. J Gastric Cancer 11:16–22PubMedCrossRefGoogle Scholar
  3. 3.
    Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L, Olijnichenko G et al (2011) Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol 13:133–138PubMedCrossRefGoogle Scholar
  4. 4.
    Christopoulos A, Ahn SM, Klein JD, Kim S (2011) Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 33:1220–1229PubMedCrossRefGoogle Scholar
  5. 5.
    Al-Rawi MA, Mansel RE, Jiang WG (2005) Molecular and cellular mechanisms of lymphangiogenesis. Eur J Surg Oncol 31:117–121PubMedCrossRefGoogle Scholar
  6. 6.
    Nagahashi M, Ramachandran S, Rashid OM, Takabe K (2010) Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol 16:4003–4012PubMedCrossRefGoogle Scholar
  7. 7.
    Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215PubMedCrossRefGoogle Scholar
  8. 8.
    Chen J, Li T, Wu Y, He L, Zhang L, Shi T et al (2011) Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 137:1799–1812PubMedCrossRefGoogle Scholar
  9. 9.
    Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D et al (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426–430PubMedCrossRefGoogle Scholar
  10. 10.
    Han FH, Li HM, Zheng DH, He YL, Zhan WH (2010) The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 36:1172–1179PubMedCrossRefGoogle Scholar
  11. 11.
    Ding S, Lin S, Dong X, Yang X, Qu H, Huang S et al (2005) Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo (Athens, Greece) 19:793–795Google Scholar
  12. 12.
    Werther K, Christensen IJ, Nielsen HJ (2002) Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417–423PubMedCrossRefGoogle Scholar
  13. 13.
    Bouvier AM, Sant M, Verdecchia A, Forman D, Damhuis R, Willem Coebergh J et al (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 46:1086–1092PubMedCrossRefGoogle Scholar
  14. 14.
    Bentrem D, Gerdes H, Tang L, Brennan M, Coit D (2007) Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14:1853–1859PubMedCrossRefGoogle Scholar
  15. 15.
    Washington K (2010) 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17:3077–3079PubMedCrossRefGoogle Scholar
  16. 16.
    Mazumdar M, Smith A, Bacik J (2003) Methods for categorizing a prognostic variable in a multivariable setting. Stat Med 22:559–571PubMedCrossRefGoogle Scholar
  17. 17.
    De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E et al (2004) Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100:270–278PubMedCrossRefGoogle Scholar
  18. 18.
    Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S et al (2003) Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194:119–124PubMedCrossRefGoogle Scholar
  19. 19.
    Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ (2004) Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 100:1385–1392CrossRefGoogle Scholar
  20. 20.
    Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sanchez Hernandez I, Munoz Molina GM et al (2009) Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 28:393–398Google Scholar
  21. 21.
    Zusterzeel PL, Span PN, Dijksterhuis MG, Thomas CM, Sweep FC, Massuger LF (2009) Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. J Cancer Res Clin Oncol 135:283–290PubMedCrossRefGoogle Scholar
  22. 22.
    Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R et al (2009) High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 96:1443–1451PubMedCrossRefGoogle Scholar
  23. 23.
    Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C et al (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37–42PubMedCrossRefGoogle Scholar
  24. 24.
    Tamura M, Ohta Y (2003) Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 98(6):1217–1222PubMedCrossRefGoogle Scholar
  25. 25.
    Yu XM, Lo CY, Lam AK, Leung P, Luk JM (2008) Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 247:483–489PubMedCrossRefGoogle Scholar
  26. 26.
    Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Banas T (2007) Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 249:171–177PubMedCrossRefGoogle Scholar
  27. 27.
    Wang TB, Deng MH, Qiu WS, Dong WG (2007) Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 13:1794–1797PubMedGoogle Scholar
  28. 28.
    Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J et al (2009) High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res 15:1741–1746PubMedCrossRefGoogle Scholar
  29. 29.
    Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J (2009) Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients. Int J Colorectal Dis 24:269–274PubMedCrossRefGoogle Scholar
  30. 30.
    Sung JY, Lee S, Kim YW, Park YK (2008) Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma. Oncol Rep 19:939–944PubMedGoogle Scholar
  31. 31.
    Mouawad R, Spano JP, Comperat E, Capron F, Khayat D (2009) Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 45:1407–1414PubMedCrossRefGoogle Scholar
  32. 32.
    Kirk R (2011) Targeted therapies: should we be aghast at the AVAGAST data? Nat Rev Clin Oncol 8:567PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • Pedro Villarejo-Campos
    • 1
    Email author
  • David Padilla-Valverde
    • 1
  • Raúl Martin Martin
    • 2
  • Pablo Menéndez-Sánchez
    • 1
  • Teófilo Cubo-Cintas
    • 1
  • Jose Antonio Bondia-Navarro
    • 3
  • Jesús Martín Fernández
    • 1
  1. 1.Hospital Universitario de Ciudad RealCiudad RealSpain
  2. 2.Área de Estadística e Innovación Operativa. Departamento de MatemáticasUniversidad de Castilla-La ManchaCastilla La ManchaSpain
  3. 3.Facultad de MedicinaUniversidad de MálagaMálagaSpain

Personalised recommendations